Heart failure with preserved ejection fraction (HFpEF)
Heart failure · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
HF symptoms/signs with LVEF >=50% and objective evidence of raised filling pressures (echo/natriuretic peptides). Typically elderly, hypertensive, obese, diabetic, often with AF. Management targets congestion, comorbidities and now SGLT2i.
Red flags
- Recurrent flash pulmonary oedema / SCAPE
- Rapid AF precipitating decompensation
- Low-flow low-gradient AS masquerading as HFpEF
- Red-flag features of amyloidosis (bilateral carpal tunnel, low voltage ECG + thick walls)
- Syncope / conduction disease
Assessment
Differential diagnosis
- HFrEF / HFmrEF
- Constrictive pericarditis
- Cardiac amyloidosis / infiltrative restrictive cardiomyopathy
- Severe valvular disease (AS, MR)
- High-output states
- Non-cardiac dyspnoea (COPD, obesity, deconditioning, PE)
Investigations
- Echocardiogram — LVEF >=50%, LA enlargement, LV hypertrophy, E/e', diastolic indices
- NT-proBNP/BNP (may be lower than HFrEF, esp. in obesity — normal does not exclude)
- ECG (AF, LVH, low voltage/pseudo-infarct suggesting amyloid)
- U&E, FBC, TFTs, HbA1c, ferritin/TSAT
- CXR
- HFA-PEFF or H2FPEF score to support diagnosis; consider exercise/stress echo or invasive haemodynamics if uncertain
- Screen for cardiac amyloid if red-flags (bone scintigraphy/DPD, serum free light chains)
Management
- Confirm diagnosis: symptoms + LVEF >=50% + raised filling pressure evidence (echo/NP/invasive)
- Decongest with loop diuretic titrated to euvolaemia
- Aggressively treat hypertension to target and manage AF (rate/rhythm, anticoagulate per CHA2DS2-VASc)
- Start an SGLT2i — now a cornerstone across the EF spectrum
- Weight loss, exercise rehabilitation, treat sleep apnoea, diabetes, iron deficiency
- Exclude and specifically treat mimics — especially cardiac amyloidosis (tafamidis) and constriction (pericardiectomy)
Drugs & doses
Dapagliflozin 10 mg PO once daily (SGLT2i — DELIVER) OR Empagliflozin 10 mg PO once daily (EMPEROR-Preserved)
Furosemide 20-40 mg PO once/twice daily titrated to congestion
Spironolactone 25 mg PO once daily (MRA — consider, esp. if LVEF <55-60%; monitor K+)
Finerenone 10-20 mg PO once daily (non-steroidal MRA — FINEARTS-HF benefit in LVEF >=40%) [verify local availability/dose]
Antihypertensives to target BP (ACEi/ARB, CCB, thiazide-like e.g. indapamide 2.5 mg PO once daily)
Rate control for AF: bisoprolol 2.5-5 mg PO once daily or diltiazem (avoid if LVEF borderline) [verify]
Anticoagulation for AF: apixaban 5 mg PO BD (2.5 mg BD if >=2 of age >=80, weight <=60 kg, creatinine >=133)
Disposition
Outpatient optimisation of diuretics, SGLT2i and comorbidities; admit for acute decompensation or arrhythmia. Refer to cardiology/HF clinic, and specifically work up amyloid/constriction where suspected.
Complications & pitfalls
- Recurrent HF admissions
- Atrial fibrillation and thromboembolism
- Pulmonary hypertension and right heart failure
- Renal dysfunction from over-diuresis
- Progression if underlying infiltrative disease untreated
Exam pearls
- SGLT2i are the first class to show consistent benefit in HFpEF (EMPEROR-Preserved, DELIVER) — now guideline-recommended across the EF spectrum.
- Beta-blockers and RAS blockers have NOT shown clear mortality benefit in true HFpEF — use them to treat comorbidities (HTN, AF, CAD), not the HFpEF itself.
- Always exclude cardiac amyloidosis — missing it denies a patient disease-modifying tafamidis.
- Over-diuresis is a common harm — HFpEF patients are preload-dependent and prone to pre-renal AKI and hypotension.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.